SCHEMBL1720195

SCHEMBL1720195

Cc1ccc(C(=O)C2CCCCC2=O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.70
MAPK1 P28482 1/20 0.69
RAB9A P51151 5/20 0.56
NPC1 O15118 4/20 0.56
GAA P10253 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 3/20 0.50
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
HPGD P15428 2/20 0.46
CYP2D6 P10635 1/20 0.46
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALDH1A1 P00352 3/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10885557 0.91 MCL1 (0.82) MCL1MAPK1RAB9ANPC1GAA
SCHEMBL27314925 0.83 MCL1 (0.70) MCL1MAPK1RAB9ANPC1GAA
SCHEMBL1720821 0.83 MCL1 (0.70) MCL1MAPK1RAB9ANPC1ALDH1A1
SCHEMBL8144387 0.83 MCL1 (0.70) MCL1MAPK1SMN1; SMN2LMNAKMT2A
SCHEMBL600072 0.82 MCL1 (1.00) MCL1MAPK1GAASMN1; SMN2LMNA
SCHEMBL1720192 0.82 MAPK1 (0.64) MCL1MAPK1RAB9ASMN1; SMN2LMNA
SCHEMBL28357763 0.82 MAPK1 (0.64) MCL1MAPK1RAB9ANPC1GAA
SCHEMBL7920767 0.82 MAPK1 (1.00) MCL1MAPK1RAB9ANPC1GAA
SCHEMBL8138263 0.81 MCL1 (0.68) MCL1MAPK1SMN1; SMN2LMNAKMT2A
SCHEMBL8131947 0.81 MCL1 (0.68) MCL1MAPK1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569904-B1 SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) 2012-01-11 EP disclosed
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
EP-1569904-A4 SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCE (CN) 2008-04-16 EP disclosed
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity LU XIAN-PING 2008-02-28 US disclosed
US-7268157-B2 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) 2007-09-11 US disclosed
EP-1569904-A1 SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY Shenzhen Chipscreen Biosciences Ltd. (CN) 2005-09-07 EP disclosed
US-20040142921-A1 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) 2004-07-22 US disclosed
WO-2004048333-A1 SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (US) 2004-06-10 WO disclosed
US-4652559-A ANALGESIC, ANTIDEPRESSANT THE UPJOHN COMPANY (US) 1987-03-24 US disclosed
US-4540690-A ANALGESICS, ANTIDEPRESSANTS THE UPJOHN COMPANY (US) 1985-09-10 US disclosed
EP-0085811-A1 2-(Phenylmethylene)cycloalkylamines THE UPJOHN COMPANY (US) 1983-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142921-A1 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity GPR119, PPARG, PPARA MCL1 1963/4885MAPK1 858/4885RAB9A 3922/4885
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity GPR119, PPARG, PPARA MCL1 2361/4885MAPK1 997/4885RAB9A 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.